Literature DB >> 9790420

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

D J Fryauff1, S Tuti, A Mardi, S Masbar, R Patipelohi, B Leksana, K C Kain, M J Bangs, T L Richie, J K Baird.   

Abstract

Malariometric surveys were conducted during July 1996 in native Dayak villages and predominantly Javanese transmigration settlements in Ketapang district of West Kalimantan, Indonesia. Malaria prevalence ranged from 0.9% to 2.7% in Dayak villages and from 1% to 20% in the transmigration settlements. Plasmodium falciparum accounted for 67% of the cases among Dayaks but P. vivax was dominant among transmigrants, accounting for more than 72% of the infections. Chloroquine sensitivity/resistance was assessed by 28-day in vivo testing of uncomplicated malaria infections and measurement of chloroquine blood levels in cases where parasitemias reappeared within the 28-day test period. Resistance was based on the appearance of asexual parasites against chloroquine plus desethylchloroquine levels exceeding the minimally effective whole blood concentrations proposed for sensitive parasite strains (P. vivax, 100 ng/ml; P. falciparum, 200 ng/ml). All parasitemias cleared initially within four days of beginning supervised chloroquine therapy (25 mg base/kg over a 48-hr period), but asexual parasites reappeared within 28 days in 27 of 52 P. vivax and three of 12 P. falciparum cases. Chloroquine blood levels at the time of recurrent parasitemias revealed resistance in 12 of the 27 P. vivax cases and in one of the three P. falciparum cases. Genotypes of nine of the 12 recurrent P. vivax isolates matched with their primary isolates and ruled out reinfection. These findings establish the presence of chloroquine-resistant P. vivax on the island of Borneo. The pattern of malaria and the high frequency of chloroquine resistance by P. vivax at the West Kalimantan location may relate to demographic, ecologic, agricultural, and socioeconomic changes associated with transmigration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790420     DOI: 10.4269/ajtmh.1998.59.513

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  32 in total

1.  Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Authors:  Moritz Treiber; Gunther Wernsdorfer; Ursula Wiedermann; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

Review 2.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 3.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

5.  Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.

Authors:  Céline Barnadas; Arsène Ratsimbasoa; Magali Tichit; Christiane Bouchier; Martial Jahevitra; Stéphane Picot; Didier Ménard
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 6.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

7.  Monitoring of failure of chloroquine treatment for Plasmodium vivax using polymerase chain reaction in Sanliurfa province, Turkey.

Authors:  Fuat Dilmec; M Ali Kurcer; Feridun Akkafa; Zeynep Simsek
Journal:  Parasitol Res       Date:  2010-02-06       Impact factor: 2.289

8.  Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.

Authors:  Inge Sutanto; Dedeh Endawati; Liem Hui Ling; Ferdinand Laihad; Rianto Setiabudy; J Kevin Baird
Journal:  Malar J       Date:  2010-02-12       Impact factor: 2.979

9.  Analysis of the dihydrofolate reductase-thymidylate synthase gene sequences in Plasmodium vivax field isolates that failed chloroquine treatment.

Authors:  Won-Ja Lee; Hyung-Hwan Kim; Yien-Kyoung Choi; Kyung-Mi Choi; Mi-A Kim; Jung-Yeon Kim; Jetsumon Sattabongkot; Youngjoo Sohn; Hyuck Kim; Jong-Koo Lee; Han-Sook Park; Hyeong-Woo Lee
Journal:  Malar J       Date:  2010-11-18       Impact factor: 2.979

Review 10.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.